EcoDrugPlus

Prostaglandin E2 Receptor Ep4 Subtype-Like

Ensembl ID : ENSOTSG00005018535
Gene Symbol: LOC112262609
3 Cross references
196 Possible Orthologues:

Prostaglandin E2 Receptor Ep4 Subtype-Like

Ensembl ID : ENSOTSG00005045274
Gene Symbol: LOC112248801
3 Cross references
196 Possible Orthologues:

Prostaglandin F Receptor (Fp)

Ensembl ID : ENSOTSG00005029905
Gene Symbol: PTGFR
1 Cross references
194 Possible Orthologues:

Prostaglandin F2-Alpha Receptor-Like

Ensembl ID : ENSOTSG00005032805
Gene Symbol: LOC112253258
3 Cross references
194 Possible Orthologues:

Prostaglandin G/h Synthase 2-Like

Ensembl ID : ENSOTSG00005023806
Gene Symbol: LOC112250956
3 Cross references
203 Possible Orthologues:

Prostaglandin I2 Receptor

Ensembl ID : ENSOTSG00005043672
Gene Symbol: PTGIR
1 Cross references
181 Possible Orthologues:

Prostaglandin I2 Receptor

Ensembl ID : ENSOTSG00005015523
Gene Symbol: PTGIR
1 Cross references
181 Possible Orthologues:

Prostaglandin-Endoperoxide Synthase 1

Ensembl ID : ENSOTSG00005047998
Gene Symbol: PTGS1
1 Cross references
206 Possible Orthologues:

Prostaglandin-Endoperoxide Synthase 1

Ensembl ID : ENSOTSG00005010939
Gene Symbol: PTGS1
3 Cross references
206 Possible Orthologues:

Prostaglandin-Endoperoxide Synthase 2

Ensembl ID : ENSOTSG00005025813
Gene Symbol: PTGS2
3 Cross references
202 Possible Orthologues:

Prostaglandin-Endoperoxide Synthase 2a

Ensembl ID : ENSOTSG00005035249
Gene Symbol: PTGS2A
1 Cross references
156 Possible Orthologues:

Prostaglandin-Endoperoxide Synthase 2a

Ensembl ID : ENSOTSG00005022172
Gene Symbol: PTGS2A
1 Cross references
156 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).